Neuron23
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
343 Oyster Point Blvd Ste 120, South San...Website
www.neuron23.comRevenue
$10.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Neuron23
Neuron23 Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 leverages recent advances in human genetics, combined with their state-of-the-art artificial intelligence (AI)-enabled drug discovery and biomarker platforms, to advance therapeutics for devastating diseases. The company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases.Explore more
Neuron23 Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neuron23 your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Neuron23, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Neuron23 has recently received funding, and reach out quickly before it becomes old news!
Click to see if Neuron23 had a recent Job posting/layoffs
Earning: See what the market has to say on Neuron23 recently announced quarterly report
Funding: Get notified immidiatlly once Neuron23 has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Neuron23 launches new products
Check out if Neuron23 is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Neuron23
Recommended Actions
Find VP level buyers at Neuron23
Find more new buyers
Compare Similar Companies to Neuron23
Compare insights from companies similar to Neuron23, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$26.4M
51-200
Public
$496M
2018
HB
Harold BernsteinPresident, Research & Chief Medical Officer, Development
Company Profile Activity
Activity Insights
Neuron23 is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Neuron23 is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Neuron23.
Neuron23 financials insights
Gather financial insights about Neuron23, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$33.5M
Series B
$80M
2022
Series C
$100M
2025
Series D
$96.5M
Neuron23 Tech Stack
A closer look at the technologies used by Neuron23
See more technologies
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Executive Move
Executive Moves, Board of Directors
Open Position
New Hire
Executive Move
Neuron23 News & Media
Neuron23 Announces Publication in PNAS Highlighting the Important Role of TYK2 in Neuroimmunology
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #TYK2--Neuron23 has announced the publication of a manuscript in PNAS exploring the role of TYK2 inhibition in multiple sclerosis (MS) and neuroinflammation.Neuron23 Announces First-in-human Dose in Phase 1 Clinical Trial of NEU-111, a TYK2 Inhibitor with Best-in-class Potential for Immune-mediated Inflammatory Disorders
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #TYK2--Neuron23 announced initiation of dosing in a Phase 1 clinical trial of NEU-111, a potent and selective inhibitor of tyrosine kinase 2 (TYK2).Neuron23 Unveils Groundbreaking Phase 2 Trial in Early Parkinson’s Disease
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #LRRK2--Neuron23 unveiled details around its global Phase 2 NEULARK clinical trial of NEU-411 in people with early Parkinson’s disease.Neuron23 Announces Usage of Roche’s Digital Biomarker and Device in Parkinson’s Disease Clinical Trial
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #LRRK2--Neuron23 is using a Roche-developed digital biomarker as the primary endpoint in the Phase 2 NEULARK trial of NEU-411 in early Parkinson’s disease.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Neuron23
Sign Up For FreeTo access detailed company insights
Neuron23 Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 leverages recent advances in human genetics, combined with their state-of-the-art artificial intelligence (AI)-enabled drug discovery and biomarker platforms, to advance therapeuti... Read More
